Literature DB >> 17656464

Transforming growth factor-beta blocks inhibin binding to different target cell types in a context-dependent manner through dual mechanisms involving betaglycan.

Paul G Farnworth1, Yao Wang, Ruth Escalona, Pauline Leembruggen, Guck T Ooi, Jock K Findlay.   

Abstract

Inhibin antagonizes activin and bone morphogenetic protein actions by sequestering their type II receptors in high-affinity complexes with betaglycan, a coreceptor that inhibin shares with TGF-beta. To clarify the nature and extent of interactions between inhibin and TGF-beta, we therefore examined 1) the mutual competition between these ligands for binding, 2) the regulation of endogenous betaglycan expression by inhibin and TGF-beta isoforms, and 3) the consequences of such betaglycan regulation for subsequent inhibin binding in mouse Leydig (TM3), Sertoli (TM4), adrenocortical cancer (AC), and gonadotroph (LbetaT2) cell lines, chosen to model cellular targets for local and endocrine actions of inhibin. Recognized inhibin, activin, and TGF-beta binding proteins and TGF-beta/activin signaling components were expressed by all four cell types, but AC and LbetaT2 cells notably lacked the type II receptor for TGF-beta, TbetaRII. Overnight treatment of TM3 and TM4 cells with TGF-beta1 suppressed the levels of betaglycan mRNA by 73 and 46% of control and subsequent [(125)I]inhibin A binding by 64 and 41% of control (IC(50) of 54 and 92 pm), respectively. TGF-beta2 acted similarly. TGF-beta pretreatments commensurately decreased the [(125)I]inhibin A affinity labeling of betaglycan on TM3 and TM4 cells. TGF-beta isoforms as direct competitors blocked up to 60% of specific inhibin A binding sites on TM3 and TM4 cells but with 9- to 17-fold lower potency than when acting indirectly via regulation of betaglycan. Only the competitive action of TGF-beta was observed with TbetaRII-deficient AC and LbetaT2 cells. Neither inhibin A nor inhibin B regulated betaglycan mRNA or competed for binding of [(125)I]TGF-beta1 or -beta2. Thus, inhibin binding to its target cell types is controlled by TGF-beta through dual mechanisms of antagonism, the operation of which vary with cell context and display different sensitivities to TGF-beta. In contrast, TGF-beta binding is relatively insensitive to the presence of either inhibin A or inhibin B.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17656464     DOI: 10.1210/en.2007-0155

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

1.  Multiple Soluble TGF-β Receptors in Addition to Soluble Endoglin Are Elevated in Preeclamptic Serum and They Synergistically Inhibit TGF-β Signaling.

Authors:  Yao Wang; Qi Chen; Min Zhao; Kelly Walton; Craig Harrison; Guiying Nie
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

2.  Phylogenomic analyses reveal the evolutionary origin of the inhibin alpha-subunit, a unique TGFbeta superfamily antagonist.

Authors:  Jie Zhu; Edward L Braun; Satomi Kohno; Monica Antenos; Eugene Y Xu; Robert W Cook; S Jack Lin; Brandon C Moore; Louis J Guillette; Theodore S Jardetzky; Teresa K Woodruff
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

3.  Endogenous betaglycan is essential for high-potency inhibin antagonism in gonadotropes.

Authors:  Ezra Wiater; Kathy A Lewis; Cynthia Donaldson; Joan Vaughan; Louise Bilezikjian; Wylie Vale
Journal:  Mol Endocrinol       Date:  2009-04-16

4.  Genetic mechanisms underlying spermatic and testicular traits within and among cattle breeds: systematic review and prioritization of GWAS results.

Authors:  Pablo Augusto de Souza Fonseca; Fernanda Caroline Dos Santos; Stephanie Lam; Aroa Suárez-Vega; Filippo Miglior; Flavio S Schenkel; Luiza de Almeida Ferreira Diniz; Samir Id-Lahoucine; Maria Raquel Santos Carvalho; Angela Cánovas
Journal:  J Anim Sci       Date:  2018-12-03       Impact factor: 3.159

5.  Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells.

Authors:  Maree Bilandzic; Simon Chu; Paul G Farnworth; Craig Harrison; Peter Nicholls; Yao Wang; Ruth M Escalona; Peter J Fuller; Jock K Findlay; Kaye L Stenvers
Journal:  Mol Endocrinol       Date:  2009-01-22

6.  Inhibin B suppresses anoikis resistance and migration through the transforming growth factor-β signaling pathway in nasopharyngeal carcinoma.

Authors:  Guoying Zou; Biqiong Ren; Yi Liu; Yin Fu; Pan Chen; Xiayu Li; Shudi Luo; Junyu He; Ge Gao; Zhaoyang Zeng; Wei Xiong; Guiyuan Li; Yumei Huang; Keqian Xu; Wenling Zhang
Journal:  Cancer Sci       Date:  2018-10-20       Impact factor: 6.716

7.  TGFBR3L is an inhibin B co-receptor that regulates female fertility.

Authors:  Emilie Brûlé; Ying Wang; Yining Li; Yeu-Farn Lin; Xiang Zhou; Luisina Ongaro; Carlos A I Alonso; Evan R S Buddle; Alan L Schneyer; Chang-Hyeock Byeon; Cynthia S Hinck; Natalia Mendelev; John P Russell; Mitra Cowan; Ulrich Boehm; Frederique Ruf-Zamojski; Michel Zamojski; Cynthia L Andoniadou; Stuart C Sealfon; Craig A Harrison; Kelly L Walton; Andrew P Hinck; Daniel J Bernard
Journal:  Sci Adv       Date:  2021-12-15       Impact factor: 14.957

8.  Betaglycan (TβRIII) is expressed in the thymus and regulates T cell development by protecting thymocytes from apoptosis.

Authors:  German R Aleman-Muench; Valentin Mendoza; Kaye Stenvers; Eduardo A Garcia-Zepeda; Fernando Lopez-Casillas; Chander Raman; Gloria Soldevila
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

9.  Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer.

Authors:  P Balanathan; E D Williams; H Wang; J S Pedersen; L G Horvath; M G Achen; S A Stacker; G P Risbridger
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

10.  Induction of transforming growth factor beta receptors following focal ischemia in the rat brain.

Authors:  Gabriella Pál; Gábor Lovas; Arpád Dobolyi
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.